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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, which includes a spectrum of
hepatic pathology such as simple steatosis, steatohepatitis, fibrosis and cirrhosis. The increased serum levels of
homocysteine (Hcy) may be associated with hepatic fat accumulation. Genetic mutations in the folate route may
only mildly impair Hcy metabolism. The aim of this study was to investigate the relation between liver steatosis
with plasma homocysteine level and MTHFR C677T and A1298C polymorphisms in Brazilian patients with NAFLD.
Methods: Thirty-five patients diagnosed with NAFLD by liver biopsy and forty-five healthy controls neither age nor
sex matched were genotyped for C677T and A1298C MTHFR polymorphisms using PCR-RFLP and PCR-ASA,
respectively, and Hcy was determined by HPLC. All patients were negative for markers of Wilson’s,
hemochromatosis and autoimmune diseases. Their daily alcohol intake was less than 100 g/week. A set of
metabolic and serum lipid markers were also measured at the time of liver biopsies.
Results: The plasma Hcy level was higher in NAFLD patients compared to the control group (p = 0.0341). No
statistical difference for genotypes 677C/T (p = 0.110) and 1298A/C (p = 0.343) in patients with NAFLD and control
subjects was observed. The genotypes distribution was in Hardy-Weinberg equilibrium (677C/T p = 0.694 and 1298
A/C p = 0.188). The group of patients and controls showed a statistically significant difference (p < 0.001) for BMI
and HOMA_IR, similarly to HDL cholesterol levels (p < 0,006), AST, ALT, γGT, AP and triglycerides levels (p < 0.001).
A negative correlation was observed between levels of vitamin B12 and Hcy concentration (p = 0.005).
Conclusion: Our results indicate that plasma Hcy was higher in NAFLD than controls. The MTHFR C677T and
A1298C polymorphisms did not differ significantly between groups, despite the 677TT homozygous frequency was
higher in patients (17.14%) than in controls (677TT = 4.44%) (p > 0.05). The suggested genetic susceptibility to the
MTHFR C677T and A1298C should be confirmed in large population based studies.
Keywords: Fatty liver, Non-alcoholic steatohepatitis, Methylenetetrahydrofolate reductase (MTHFR), Oxidative stress,
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Background
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver
disease, which presents a spectrum of hepatic pathology
including simple steatosis, steatohepatitis (NASH), fibro-
sis, and cirrhosis [1]. NALFD is now the most common
cause of abnormal liver biochemistry in North America
[2] and is also known to be associated with some drugs,
genetic defects, obesity, insulin resistance and type 2 dia-
betes [3]. The accumulation of triglycerides in the liver in
the absence of excess alcohol intake has been described in
the early sixties [4] and predominantly characterized by
macrovesicular hepatic steatosis [5].
The two metabolic abnormalities mostly associated
with NAFLD are insulin resistance (IR) and an increased
supply of fatty acids to the liver [6,7]. As adipose tissue
becomes resistant to insulin, serum lipoprotein levels
shift and flux of free fatty acids to the liver increases
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[8,9]. The cumulative effects of insulin resistance and in-
creased circulating free fatty acids act in concert to
channel fatty acids into storage rather than into
secretory and pathways of degradation [10,11]. There-
fore, it is mainly associated with other clinical expres-
sions of IR, such as metabolic syndrome and its features,
as obesity, type 2 diabetes, dyslipidemia and hyperten-
sion [12].
In addition, it has been reported that Hyperhomocysteinemia
(HHcy) alters intracellular lipid metabolism [13]. Thus
the data support the view that increased serum levels of
homocysteine (Hcy) may be associated with hepatic fat
accumulation. Homocysteine is a sulphur-containing
amino acid, which is an intermediate product in the
normal biosynthesis of the amino acids methionine and
cysteine [14].
Some genetic mutations in the folate route may mildly
impair homocysteine metabolism [4,15]. The genomic
DNA methylation directly correlates with folate status
and inversely, with plasma homocysteine levels. The
methylenetetrahydrofolate reductase (MTHFR) polymor-
phisms influence DNA methylation status through an
interaction with folate status [15]. Mutations in MTHFR
gene (C677T and A1298C) result in amino acids substi-
tutions that lead to a decreased enzyme activity, redu-
cing the 5 mTHF availability [16]. The MTHFR C677T
and A1298C polymorphisms have been shown to be as-
sociated with higher levels of homocysteine, when
plasma folate levels are low [16,17].
Several studies have been conducted in order to find a
relationship between the presence of MTHFR polymor-
phisms and disease risk. The C677T and A1298C poly-
morphisms affect a large portion of the population with
considerable variations between different ethnic groups
[18]. Although Brazil has become the object of interest
in population genetic studies because of phenotypic
and social differences observed among populations
from five geographic regions of the country, studies
with MTHFR C677T and A1298C polymorphisms in
Brazilian population are necessary, especially when as-
sociated with NAFLD. Therefore, the aim of this study
was to investigate the relation between liver steatosis
with plasma homocysteine levels and MTHFR C677T
and A1298C polymorphisms in patients with NAFLD
from Northeast Brazil.
Methods
This study comprised 35 patients with a diagnosis of
NAFLD based on liver biopsy findings (09 males and 26
females, age mean 49 years) and 51 healthy subjects,
without NAFLD (16 males and 35 females, age mean
39 years), according to ultrasound findings at the Liver
Institute of Pernambuco – Brazil between 2005 to
2008. In addition, all patients had elevated alanine
aminotransferase (ALT) and/or aspartate aminotransferase
(AST) levels at least on two occasions, over 6 months
prior to enrollment. The study protocol was approved by
the Ethics Committee for Human Hesearch of the Univer-
sity of Pernambuco and a written consent was obtained
from every individual participating in the study. This
transversal study was conducted in accordance with the
Helsinki declaration of 2008.
All patients were negative for markers of Wilson’s dis-
ease, hemochromatosis and autoimmune diseases and
had current and past daily alcohol intake kept under
100 g/week. Patients who were hepatitis B surface anti-
gen– and/or HIV-positive and had other potential causes
of liver disease were excluded. Patients with clinically
decompensated cirrhosis or contraindications for liver
biopsy were not included in the study.
None of the patients were taking medication that could
cause steatosis (salicylates, nonsteroidal anti-inflammatory
drugs, corticosteroids, valproic acid, amiodarone, perhexiline
maleate) or modify serum levels of homocysteinemia (folate,
vitamin B12).
Diagnosis of type 2 diabetes and dyslipidemia were based
on the criteria of the American Diabetes Association
(fasting glucose ≥ 100 mg/dL; Triglyceride ≥ 150 mg/dL
HDL < 40 mg/dl in man or < 50 mg/dL in woman)
[19]. Overweight corresponded to Body Mass Index
(BMI) > 25 kg/m2 and obesity to BMI ≥ 30 kg/m2.
Laboratory assays
Blood samples were collected after fasting overnight and
centrifuged within 60 min to separate plasma, serum
and leukocyte cells and storaged at – 80°C.
Fasting Glucose, total cholesterol and fractions, triglyc-
erides, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (AP), γGT were
performed by standard methods using automated tech-
niques (Modular P800, Hitach/Roche) in all patients at
basal line and at the end of the study.
The homocysteine levels were determined by HPLC
(high performance liquid cromatography) with fluori-
metric detection [20]. The folic acid and B12 vitamin
were determined by standard methods using automated
techniques (Elecsys and COBAS analyzers/Roche).
The insulin resistance index was calculated based on
fasting insulin and fasting glucose according to homeo-
stasis model assessment (HOMA -IR) [21]. The Body
Mass Index (BMI) is defined as the individual’s body
mass divided by the square of his or her height.
For MTHFR polymorphism identification, the DNA was
extracted from leukocytes by the salting out method. The
C677T and A1298C MTHFR polymorphisms were deter-
mined by PCR-RFLP (Hinf I) and PCR-ASA, respectively
[22,23]. The amplified and digested fragments were ana-
lyzed in 3% agarose gel and the fragments were visualized
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in ultraviolet light (UV) after being stained with ethidium
bromide. The 677 wild type (CC) shows a single fragment
of 198 bp; heterozygote (CT) shows fragments of 198, 175
and 23 bp; and mutant homozygote (TT) shows two frag-
ments with 175 and 23 bp [22]. The polymorphism
MTHFR A1298C wild type and mutated alleles yield frag-
ments of 77-bp and 120-bp, respectively [23].
Histological analysis
A single liver pathologist scored all specimens with ex-
pertise in NAFLD: macro and microvacuolar fatty
change, zonal distribution, foci of necrosis, portal and
perivenular fibrosis, inflammatory and fibrotic infiltrate
with zonal distribution. Macrovesicular steatosis was
classified in low steatosis (<33% of hepatocytes with
steatosis), moderate (34-66%) and intense (>66%) [24].
Statistical analysis
Data analysis was performed with BioEstat 5.0 software.
The quantitative variables were described by mean
values ± SD. T-test and Mann–Whitney U test were
used in variables with normal and without normal distri-
bution. Spearman’s r coefficient was used to discover a
correlation between continuous variables (folate and B12
vitamin status and homocysteine). The frequencies of
each allele were calculated as q = (2a + b)/n, where a
corresponded to the number of homozygotes, b to the
number of heterozygotes, and n to the number of alleles
analyzed, respectively. Hardy-Weinberg equilibrium was
tested for the SNP by comparing observed frequencies
with expected frequencies and using a χ2 test. The dif-
ferences in genotypes from each polymorphic position
between cases and controls were assessed by Fisher’s
exact tests. In all statistical evaluations, P < 0.05 was
taken as significant.
Results
Clinical and biochemical analysis
The results of the clinical and biochemistry parameters
are described in Table 1. Thirty-five patients had a
clinical and biochemical analysis completed in the
study. There were 25.7% (6/35) males and 74.3% (26/35)
females. The BMI and HOMA -IR were higher in
NAFLD patients than in control groups (p < 0.001).
Similarly to HDL cholesterol levels (p < 0,006), the
AST, ALT, γGT, AP and triglycerides levels differed
significantly in NAFLD patients as compared to con-
trols (p < 0.001).
Table 2 shows the results of B12 vitamin levels demon-
strating a significant difference between patients and
controls. In addition, when comparing NALFD patients
with controls as to Hcy levels, a significant difference
between these groups was shown (p = 0.0341).
Polymorphisms analysis
The MTHFR polymorphisms were analyzed from periph-
eral blood of 35 patients and 45 controls. The frequen-
cies of the MTHFR genotypes for both loci C677T and
A1298C and respective alleles are shown in Table 3. The
distributions of the MTHFR genotypes correspond to
those expected by Hardy-Weinberg equilibrium in both
NAFLD patients and controls indicating that the allelic
distribution was random. The genotypes CT (48.57%)
and AA (57.15%) were more frequent in NAFLD pa-
tients for C677T and A1298C, respectively. Although the
677TT homozygous frequency was higher in patients
(17.14%) than in controls (677TT = 4.44%), as expected,
the difference in genotypes distribution was not signifi-
cant (p = 0.110). No statistical differences were observed
in A1298C genotypes and alleles, either (p = 0.343). No
differences in the C677T (p = 0.110) and A1298C
(p = 0.343) MTHFR polymorphisms distributions were
found between patients and controls (Table 3).
Discussion
We designed our study based on the hypothesis that
the homozygosity for both polymorphisms, C677T and
A1298C, significantly raises the levels of plasma Hcy. How-
ever, the MTHFR C677T and A1298C polymorphisms did
Table 1 Clinical and biochemical characteristics in NAFLD
patients and controls subjects
PATIENTS (n=35) CONTROLS (n=51) P
Total Cholesterol 187.91 ± 38.83 182.27 ± 38.36 0.516
HDL 44.30 ± 13.83 53.51 ± 15.27 0.006*
LDL 115.49 ± 35.88 110.46 ± 32.38 0.509
Triglycerides 171.72 ± 80.91 93.77 ± 39.70 p< 0.001*
Fasting Glucose 99.67 ± 35.59 92.09 ± 10.50 0.167
Insulin 16.55 ± 10.74 7.12 ± 4.22 p < 0.001*
HOMA value >3.0 3.90 ± 2.75 1.65 ± 1.10 p < 0.001*
AST 54.51 ± 31.94 18.20 ± 5.93 p< 0.001*
ALT 82.15 ± 38.72 14.82 ± 8.99 p < 0.001*
GGT 126.38 ± 125.90 28.35 ± 22.61 p< 0.001*
AP 87.15 ± 53.88 63.92 ± 33.53 0.019*
BMI 29.77 ± 4.38 24.22 ± 3.68 p < 0.001*
* t-Test was applied for these groups specifically. BMI. body mass index; HDL-C.
high-density-lipoprotein cholesterol; LDL-C. Low-density- lipoprotein
cholesterol.
Table 2 Relationship among homocysteine, folate and
B12 vitamin in NAFLD patients and in control subjects
PATIENTS (n=35) CONTROLS (n=51) P
Folate 15.25 ± 3.27 15.12 ± 3.02 0.853
B12 vitamin 473.11 ± 199.40 355.02 ± 178.04 0.005
Homocystein 9.69 ± 2.89 8.49 ± 1.76 0.034
p = t-Test was applied for these groups specifically.
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not differ significantly between groups in this study. This
fact can be explained by two reasons, (1) the sample size is
small and (2) the mixing occurred in the region, since the
northeast Brazilian population was originated from African,
Caucasian and Native American ancestral individuals [25].
According to Volcik et al. (2001) the frequencies of alleles
677 T and A1298C may vary according to geographical area
and ethnic group and the difference of values observed
among populations can be explained by ethnic differences
and nutrition [26]. Our results indicated that, despite the
small number of northeastern Brazilian patients with
NAFLD in our sample, NAFLD was associated with ele-
vated plasma Hcy.
Association studies of MTHFR gene polymorphisms
and NAFLD disease, such as those of Serin (2006) and
Sazci (2008) cited, are scarce. Both studies were devel-
oped with the Turkish population [3,27]. Our study is
the first description of C677T and A1298T MTHFR
polymorphism in a sample of northeastern Brazilians
with NAFLD.
In this study there was a statistically significant differ-
ence for BMI and HOMA_IR between groups of patients
and controls, but there was no correlation between
homocysteine concentration and the other variables
studied in patients with NAFLD, except the negative
correlation observed between levels of vitamin B12 and
homocysteine concentration (p = 0.006). These results
are consistent with Gulsen et al. that also found a nega-
tive correlation between homocysteine and B12 [28],
probably because of the lower intake of essential vita-
mins such as folate and vitamin B12 in these patients
with NAFLD. Hcy can result from deficiencies of vita-
min cofactors (B6, B12, folic acid) required for Hcy me-
tabolism and/or from genetic disorders of its metabolism
[29]. These data support the view that increased serum
levels of homocysteine may be associated with hepatic fat
accumulation. Moreover, the BMI and HOMA -IR were
higher in NAFLD patients and also the relationship be-
tween Hcy and B12 vitamin was significant between
NAFLD and control group. The triglycerides levels and
HDL cholesterol were significantly different in NAFLD
patients compared to controls. Siqueira et al. (2011) re-
lated that plasma Hcy levels is highly prevalent in subjects
with chronic hepatits C with steatosis regardless of HCV
genotype and vitamin deficiency [30].
The present study shows that the plasma Hcy was
higher in patients with NAFLD than in healthy subjects,
but this study does not allow any conclusion as to
whether the increase of plasma Hcy is the cause of insu-
lin resistance and whether the plasma Hcy concentra-
tions correlates with the stage of the disease in NAFLD.
Conclusion
In conclusion, the results indicated that in patients from
Northeast Brazil, NAFLD is associated with elevated
plasma Hcy. NAFLD, apparently, was associated with
other known host features such as BMI, HOMA, and
levels of serum lipids. Further studies with larger sam-
ples need be conducted to confirm or exclude the rela-
tions found herein, as well as analyses of the MTHFR
C677T and A1298C polymorphism frequencies.
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Table 3 Genotypes and alleles frequencies of the C667T and A1298C (MTHFR) polymorphisms in NAFLD patients and
control subjects and statistical parameters
Genotypes and alleles NAFLD N (35) % P* Control N (45)% P** χ2 P***
MTHFR C677T
CC 12 (34.29) 0.996 23 (51.11) 0.360 0.154 0.345
CT 17 (48.57) 20 (44.45)
TT 06 (17.14) 02 (4.44)
CT+TT 23 (63.71) 22 (36.30)
Allele 677C 21 (0.58) 33 (0.73)
Allele 677T 14 (0.41) 12 (0.26)
MTHFR A1298C
AA 20 (57.15) 0.106 26 (57.79) 0.707 1.727 0.473
AC 15 (42.85) 17 (37.77)
CC 0 02 (4.44)
AC+CC 15 (50.31) 19 (49.68)
Allele 1298A 24 (0.78) 35 (0.76)
Allele 1298C 4 (0.21) 10 (0.23)
P* = Hardy-Weinberg Equilibrium NAFLD; P* = Hardy-Weinberg Equilibrium Control; χ2 = chi-square; P*** = Exact Fisher.
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Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SCRC participated in the all steps of study, including design of the study,
performed the statistical analysis and wrote the manuscript. MTCM
participated in the sequence alignment and drafted the manuscript. MDVS
carried out the molecular genetic studies of A1298C polymorphism. ERFS
critical revision of the manuscript for important intellectual content. AVG
critical revision of the manuscript for important intellectual content. KAS
acquisition of data, analysis and interpretation of data. LCLB carried out the
molecular genetic studies of C677T polymorphism. VDA measured the
plasma Hcy level in this study. CPMS helped to draft the manuscript. LMMBP
conceived of the study and participated in its design and coordination. All
authors read and approved the final manuscript.
Acknowledgements
The authors acknowledge the Pernambuco University, the Pediatrics
Hematology and Oncology Center of Pernambuco University, the Liver
Institute of Pernambuco, Federal University of São Paulo and Department of
Pediatrics for their help in data collection and clinical analyzes. The authors
declare that they do not have anything to disclose regarding funding from
industries or conflict of interest with respect to this manuscript.
Author details
1School of Medicine, Universityof Pernambuco, Pernambuco, Brazil.
2Pediatrics Hematology and Oncology Center, University of Pernambuco,
Pernambuco, Brazil. 3Liver Institute of Pernambuco, Pernambuco, Brazil.
4Biological Science Institute, University of Pernambuco, Pernambuco, Brazil.
5Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
6School of Medicine, University of São Paulo, São Paulo, Brazil. 7Instituto do
Fígado de Pernambuco, Arnóbio Marques Street, 310, Santo Amaro- Recife,
PE Zip Code: 50.100-130, Brazil.
Received: 15 August 2012 Accepted: 8 March 2013
Published: 2 April 2013
References
1. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults.
J Clin Gastroenterol 2006, 40:S5–S10.
2. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern
Med 1997, 126:137.S.
3. Sazci A, Ergul E, Aygun C, et al: Methylenetetrahydrofolate reductase gene
polymorphisms in patients with nonalcoholic steatohepatitis (NASH).
Cell Biochem Funct 2008, 26(3):291–296.
4. Schreuder TCMA, Verwer BJ, van Nieuwkerk CMJ, Mulder CJJ: Nonalcoholic
fatty liver disease: an overview of current insights in pathogenesis,
diagnosis and treatment. World J Gastroenterol 2008, 14(16):2474–2486.
5. Sanyal AJ, American Gastroenterological Association: AGA technical review
on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705–1725.
6. Luyckx FH, Lefebvre PJ, Scheen AJ: Non-alcoholic steatohepatitis:
association with obesity and insulin resistance, and influence of weight
loss. Diabetes Metab 2000, 26:98–106.
7. Cortez-Pinto H, Camilo ME, Baptista A, et al: Nonalcoholic fatty liver:
another feature of the metabolic syndrome? Clin Nutr 1999, 18:353–358.
8. Campbell PJ, Carlson MG, Nurjhan N: Fat metabolism in human obesity.
Am J Physiol 1994, 266:E600–E605.
9. Gibbons GF, Islam K, Pease RJ: Mobilisation of triacyglycerol stores.
Biochem Biophys Acta 2000, 1483:37–57.
10. Wiggins D, Gibbons GF: The lipolysis/esterification cycle of hepatic
triacylglycerol. Its role in the secretion of verylow-density lipoprotein
and its response to hormones and sulphonylureas. Biochem J 1992,
284:457–462.
11. Gibbons GF, Wiggins D: Intracellular triacylglycerol lipase: its role in the
assembly of hepatic very-low density lipoprotein (VLDL). Adv Enzyme
Regul 1995, 35:179–198.
12. Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver,
steatohepatitis, and the metabolic sindrome. Hepatology 2003,
37:917–923.
13. Werstuck GH, Lentz SR, Dayal S, et al: Homocysteine-induced endoplasmic
reticulum stress causes dysregulation of the cholesterol and triglyceride
biosynthetic pathways. J Clin Invest 2001, 107:1263–1273.
14. Faeh D, Chiolero A, Paccaud F: Homocysteine as a risk factor for
cardiovascular disease: should we (still) worry about it? Swiss Med Wkly
2006, 136:745–756.
15. Friso S, Girelli D, Trabetti E, et al: A1298C methylenetetrahydrofolate
reductase mutation and coronary artery disease: relationships with
C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med
2002, 2(1):7–12.
16. Silva VC, Ramos FJC, Freitas EM, et al: Alheimer’s Disease in Brazilian
elderly has a relation with homocysteine but not with MTHFR
polymorphisms. Arq Neuropsiquiatr 2006, 64(4):941–945.
17. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S:
Hyperhomocysteinaemia: an independent risk factor or a simple marker
of vascular disease? Pathol Biol 2003, 51(2):101–110.
18. Friso S, Choi SW, Girelli D, et al: A common mutation in the 5,10-
methylenetetrahydrofolate reductase gene affects genomic DNA
methylation through an interaction with folate status. Proc Natl Acad Sci
2002, 99:5606–5611.
19. American Diabetes Association: Standards of medical care in diabetes.
Diabetes Care 2011, 34(1):511–561.
20. Pfiffer CM, Huff DL, Gunter EW: Rapid and accurate HPLC assay dos pIAM
total homocysteine and cysteine in a clinical laboratorysetting. Clin Chem
1999, 454:290–292.
21. Brunt EM, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B:
Nonalcoholic steatohepatitis: a proposal for grading and staging the
histologic lesions. Am J Gastroenterol 1999, 94:2467–2474.
22. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for
vascular disease: a common mutation in methylenetetrahydrofolate
reductase. Nat Genet 1995, 10:111–113.
23. Biselli JM, Goloni-Bertollo EM, Zampieri BL, et al: Genetic polymorphisms
involved in folate metabolism and elevated plasma concentrations of
homocysteine: maternal risk factors for down syndrome in brazil. Genet
Mol Res Online J 2008, 7:33–42.
24. Ji C, Kaplowitz N: Hyperhomocysteinemia, endoplasmic reticulum stress,
and alcoholic liver injury. World J Gastroenterol 2004, 10(12):1699–1708.
25. Gomes AV, Mauricio-da-Silva L, Raposo G, Vieira JR, Silva Rdos S: 13 STR loci
frequencies in the population from Paraíba, Northeast Brazil. Forensic Sci
Int 2007, 173(2–3):231–234. 20.
26. Volcik KA, Blanton SH, Northrup H: Examinations of
methylenetetrahydrofolate Reductase C677T and A1298C mutations -
and In utero viability. Am J Hum Genet 2001, 69(5):1150–1152.
27. Serin E, Güçlü M, Ataç FB, Verdi H, Kayaselçuk F, Ozer B, Bilezikçi B, Yilmaz U:
Methylenetetrahydrofolate Reductase C677T mutation and nonalcoholic
fatty liver disease. Dig Dis Sci 2007, 52(5):1183–1186.
28. Gulsen M, Yesilova Z, Bagci S, et al: Elevated plasma homocysteine
concentrations as a predictor of steatohepatitis in patients with non-
alcoholic fatty liver disease. J Gast Hep 2005, 20:1448–1455.
29. Ji C, Kaplowitz N: Betaine decreases hyperhomocysteinemia, endoplasmic
reticulumstress, and liver injury in alcohol-fedmice. Gastroenterology 2003,
124:1488–1499.
30. Siqueira ER, Oliveira CP, Muniz MTC, Silva F, Pereira LM, Carrilho FJ:
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and
high plasma homocysteine in chronic hepatitis C (CHC) infected patients
from the Northeast of Brazil. Nutr J 2011, 19(10):86.
doi:10.1186/1475-2891-12-37
Cite this article as: de Carvalho et al.: Plasmatic higher levels of
homocysteine in Non-alcoholic fatty liver disease (NAFLD). Nutrition
Journal 2013 12:37.
de Carvalho et al. Nutrition Journal 2013, 12:37 Page 5 of 5
http://www.nutritionj.com/content/12/1/37
